TY - JOUR
T1 - Investigation of inhibition of human glucose 6-phosphate dehydrogenase by some 99mTc chelators by in silico and in vitro methods
AU - Şahin, Ali
AU - Şentürk, Murat
AU - Salmas, Ramin E.
AU - Durdagi, Serdar
AU - Ayan, Arif
AU - Karagölge, Ali
AU - Mestanoğlu, Mert
PY - 2016/5/3
Y1 - 2016/5/3
N2 - The inhibitory effects of methoxyisobutylisonitrile (MIBI), diethylene triamine pentaacetic acid (DTPA), dimercaptosuccinic acid (DMSA) and metilendifosfonat (MDP) on human erythrocyte glucose 6-phosphate dehydrogenase (hG6PD) activity were investigated. For this purpose, hG6PD was initially purified 557-fold at a yield of 51.43% using 2′,5′-adenosine diphosphate (ADP) sepharose 4B affinity gel chromatography. The in vitro effects of these chelators on hG6PD enzyme were studied. IC50 values of MIBI, DTPA, DMSA and MDP were 0.056, 0.172, 0.274 and 0.175 mM, of hG6PD, respectively. It was detected in in vitro studies that the hG6PD enzyme is inhibited due to these radiopharmaceutical chelators. In addition to in vitro studies, in order to better understand the molecular mechanism of studied compounds, combined in silico approaches, including molecular docking and molecular dynamics (MD), simulations were successfully performed. MD simulations shed light on inhibition mechanisms of the individual inhibitors into the ligand-binding pocket of hG6PD. Essential amino acids for binding are also investigated using per-residue interaction analysis studies.
AB - The inhibitory effects of methoxyisobutylisonitrile (MIBI), diethylene triamine pentaacetic acid (DTPA), dimercaptosuccinic acid (DMSA) and metilendifosfonat (MDP) on human erythrocyte glucose 6-phosphate dehydrogenase (hG6PD) activity were investigated. For this purpose, hG6PD was initially purified 557-fold at a yield of 51.43% using 2′,5′-adenosine diphosphate (ADP) sepharose 4B affinity gel chromatography. The in vitro effects of these chelators on hG6PD enzyme were studied. IC50 values of MIBI, DTPA, DMSA and MDP were 0.056, 0.172, 0.274 and 0.175 mM, of hG6PD, respectively. It was detected in in vitro studies that the hG6PD enzyme is inhibited due to these radiopharmaceutical chelators. In addition to in vitro studies, in order to better understand the molecular mechanism of studied compounds, combined in silico approaches, including molecular docking and molecular dynamics (MD), simulations were successfully performed. MD simulations shed light on inhibition mechanisms of the individual inhibitors into the ligand-binding pocket of hG6PD. Essential amino acids for binding are also investigated using per-residue interaction analysis studies.
KW - Chelator
KW - human G6PD
KW - molecular modeling
KW - radiopharmaceutical
UR - http://www.scopus.com/inward/record.url?scp=84965041818&partnerID=8YFLogxK
U2 - 10.1080/14756366.2016.1178735
DO - 10.1080/14756366.2016.1178735
M3 - Article
C2 - 27143114
AN - SCOPUS:84965041818
SN - 1475-6366
VL - 31
SP - 141
EP - 147
JO - JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
JF - JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
IS - sup1
ER -